Rana R McKay1, Lillian Werner2, Matthew Fiorillo3, Jennifer Roberts4, Elisabeth I Heath5, Glenn J Bubley6, Robert Bruce Montgomery7, Mary-Ellen Taplin3. 1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Electronic address: Rmckay5@partners.org. 2. Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA. 3. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. 4. Clinical Operations and Program Management, Tokai Pharmaceuticals, Cambridge, MA. 5. Department of Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, MI. 6. Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA. 7. Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA.
Abstract
BACKGROUND: Galeterone is a multi-targeted agent with activity as a CYP17 inhibitor, androgen receptor antagonist, and also causes androgen receptor degradation. It has shown meaningful anti-tumor activity with a well-tolerated safety profile in patients with castration-resistant prostate cancer (CRPC) in phase I and II studies; however, the efficacy of currently approved CRPC therapies after treatment with galeterone is unknown. In this study, we evaluate prostate specific antigen (PSA) response of non-protocol therapies following galeterone in a subset of patients treated on the Androgen Receptor Modulation Optimized for Response (ARMOR) 2 study. PATIENTS AND METHODS: Patients who received any subsequent treatment were included. PSA response and treatment duration were summarized by line and type of subsequent therapy. RESULTS: Overall, 27 of 40 patients received ≥ 1 post-galeterone treatment, of whom 18 (67%) discontinued galeterone for progression, 14 (52%) received ≥ 2 treatments, and 6 (22%) received ≥ 3 treatments. PSA changed by a median of -36%, -35%, and +60% in patients receiving first-line, second-line, and third-line therapy, respectively. Overall, 18 (67%) received subsequent enzalutamide, 12 (44%) received docetaxel, 9 (33%) received abiraterone, and 5 (19%) received cabazitaxel. PSA changed by a median of -27%, -34%, -39%, and 17% for patients receiving subsequent enzalutamide, docetaxel, abiraterone, and cabazitaxel, respectively, at any line. CONCLUSION: We demonstrate that CRPC therapies exhibit differential anti-tumor activity following galeterone. In this small cohort, abiraterone demonstrates the highest PSA response post-galeterone, whereas enzalutamide and chemotherapy have more modest activity. Larger clinical studies are warranted to fully evaluate the efficacy and safety of second-generation hormonal agents and chemotherapy post-galeterone. Predictive biomarkers will be critical to optimizing patient selection for sequential therapies.
BACKGROUND:Galeterone is a multi-targeted agent with activity as a CYP17 inhibitor, androgen receptor antagonist, and also causes androgen receptor degradation. It has shown meaningful anti-tumor activity with a well-tolerated safety profile in patients with castration-resistant prostate cancer (CRPC) in phase I and II studies; however, the efficacy of currently approved CRPC therapies after treatment with galeterone is unknown. In this study, we evaluate prostate specific antigen (PSA) response of non-protocol therapies following galeterone in a subset of patients treated on the Androgen Receptor Modulation Optimized for Response (ARMOR) 2 study. PATIENTS AND METHODS: Patients who received any subsequent treatment were included. PSA response and treatment duration were summarized by line and type of subsequent therapy. RESULTS: Overall, 27 of 40 patients received ≥ 1 post-galeterone treatment, of whom 18 (67%) discontinued galeterone for progression, 14 (52%) received ≥ 2 treatments, and 6 (22%) received ≥ 3 treatments. PSAchanged by a median of -36%, -35%, and +60% in patients receiving first-line, second-line, and third-line therapy, respectively. Overall, 18 (67%) received subsequent enzalutamide, 12 (44%) received docetaxel, 9 (33%) received abiraterone, and 5 (19%) received cabazitaxel. PSAchanged by a median of -27%, -34%, -39%, and 17% for patients receiving subsequent enzalutamide, docetaxel, abiraterone, and cabazitaxel, respectively, at any line. CONCLUSION: We demonstrate that CRPC therapies exhibit differential anti-tumor activity following galeterone. In this small cohort, abiraterone demonstrates the highest PSA response post-galeterone, whereas enzalutamide and chemotherapy have more modest activity. Larger clinical studies are warranted to fully evaluate the efficacy and safety of second-generation hormonal agents and chemotherapy post-galeterone. Predictive biomarkers will be critical to optimizing patient selection for sequential therapies.
Authors: Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf Journal: N Engl J Med Date: 2012-12-10 Impact factor: 91.245
Authors: Michael T Schweizer; Xian C Zhou; Hao Wang; Sunakshi Bassi; Michael A Carducci; Mario A Eisenberger; Emmanuel S Antonarakis Journal: Eur Urol Date: 2014-01-24 Impact factor: 20.096
Authors: R Bruce Montgomery; Elahe A Mostaghel; Robert Vessella; David L Hess; Thomas F Kalhorn; Celestia S Higano; Lawrence D True; Peter S Nelson Journal: Cancer Res Date: 2008-06-01 Impact factor: 12.701
Authors: Bruce Montgomery; Mario A Eisenberger; Matthew B Rettig; Franklin Chu; Roberto Pili; Joseph J Stephenson; Nicholas J Vogelzang; Alan J Koletsky; Luke T Nordquist; William J Edenfield; Khalid Mamlouk; Karen J Ferrante; Mary-Ellen Taplin Journal: Clin Cancer Res Date: 2015-11-02 Impact factor: 12.531
Authors: M A Fenton; T D Shuster; A M Fertig; M E Taplin; G Kolvenbag; G J Bubley; S P Balk Journal: Clin Cancer Res Date: 1997-08 Impact factor: 12.531
Authors: Eleni Efstathiou; Mark Titus; Sijin Wen; Anh Hoang; Maria Karlou; Robynne Ashe; Shi Ming Tu; Ana Aparicio; Patricia Troncoso; James Mohler; Christopher J Logothetis Journal: Eur Urol Date: 2014-05-29 Impact factor: 20.096
Authors: H H Cheng; R Gulati; A Azad; R Nadal; P Twardowski; U N Vaishampayan; N Agarwal; E I Heath; S K Pal; H-T Rehman; A Leiter; J A Batten; R B Montgomery; M D Galsky; E S Antonarakis; K N Chi; E Y Yu Journal: Prostate Cancer Prostatic Dis Date: 2015-01-20 Impact factor: 5.554
Authors: Urszula L McClurg; Mahsa Azizyan; Craig N Robson; Daniel T Dransfield; Nivedita Namdev; Nay C T H Chit; Sirintra Nakjang Journal: Oncotarget Date: 2018-05-18
Authors: Andrew K Kwegyir-Afful; Senthilmurugan Ramalingam; Vidya P Ramamurthy; Puranik Purushottamachar; Francis N Murigi; Tadas S Vasaitis; Weiliang Huang; Maureen A Kane; Yuji Zhang; Nicholas Ambulos; Sudhir Tiwari; Pratima Srivastava; Ivo P Nnane; Arif Hussain; Yun Qiu; David J Weber; Vincent C O Njar Journal: Cancers (Basel) Date: 2019-10-24 Impact factor: 6.639